Show simple item record

dc.contributor.authorQaseem, Amir
dc.contributor.authorYost, Jennifer
dc.contributor.authorEtxeandia-Ikobaltzeta, Itziar
dc.contributor.authorAbraham, George M
dc.contributor.authorJokela, Janet A.
dc.contributor.authorForciea, Mary Ann
dc.contributor.authorMiller, Matthew C.
dc.contributor.authorHumphrey, Linda L.
dc.date2022-08-11T08:08:11.000
dc.date.accessioned2022-08-23T15:45:31Z
dc.date.available2022-08-23T15:45:31Z
dc.date.issued2022-03-01
dc.date.submitted2022-03-16
dc.identifier.citation<p>Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Abraham GM, Jokela JA, Forciea MA, Miller MC, Humphrey LL; Scientific Medical Policy Committee of the American College of Physicians*. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2, Update Alert 3). Ann Intern Med. 2022 Mar 1. doi: 10.7326/M21-4810. Epub ahead of print. PMID: 35226518. <a href="https://doi.org/10.7326/M21-4810">Link to article on publisher's site</a></p>
dc.identifier.issn0003-4819 (Linking)
dc.identifier.doi10.7326/M21-4810
dc.identifier.pmid35226518
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27546
dc.description.abstractThis is an update of the American College of Physicians' living, rapid practice points on the use of remdesivir for treatment of COVID-19. This update is based on an updated living, rapid systematic review that included studies published through 19 October 2021 and identified 2 new studies meeting inclusion criteria.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=35226518&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://doi.org/10.7326/m21-4810
dc.subjectremdesivir
dc.subjectCOVID-19
dc.subjectHealth Services Administration
dc.subjectHealth Services Research
dc.subjectInfectious Disease
dc.subjectTherapeutics
dc.subjectVirus Diseases
dc.titleShould Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2, Update Alert 3)
dc.typeJournal Article
dc.source.journaltitleAnnals of internal medicine
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/covid19/348
dc.identifier.contextkey28374448
html.description.abstract<p>This is an update of the American College of Physicians' living, rapid practice points on the use of remdesivir for treatment of COVID-19. This update is based on an updated living, rapid systematic review that included studies published through 19 October 2021 and identified 2 new studies meeting inclusion criteria.</p>
dc.identifier.submissionpathcovid19/348
dc.contributor.departmentDepartment of Medicine


This item appears in the following Collection(s)

Show simple item record